Abstract
Inborn errors of metabolism (IEM) comprise a large group of inherited disease, some of which are due to disordered lysosomal, peroxisomal, or mitochondrial function and only some of which might be improved following HSCT.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
1 Inborn Errors of Metabolism
1.1 Definition and Epidemiology
Inborn errors of metabolism (IEM) comprise a large group of inherited disease, some of which are due to disordered lysosomal, peroxisomal, or mitochondrial function and only some of which might be improved following HSCT. This review will be limited to the commoner indications reported in HSCT registries and which together account for the most transplanted IEM.
1.2 Diagnosis
Timely diagnosis is imperative in IEM since in all such diseases HSCT is better at preventing disease progression than reversing established disease manifestations.
Diagnosis is made in three ways:
-
Through early recognition of disease manifestations
-
Through screening of presymptomatic individuals within a known affected kindred
-
Population screening for disease, such as in the neonatal period
1.3 Classification (See Table 90.1)
1.4 Risk Factors
Patient performance score at transplant predicts transplant outcome. Patients with an adverse performance score at transplant also have an inferior long-term survival as the transplant fails in advanced disease to prevent disease progression.
1.5 Prognostic Index
Not available
1.6 First-Line Treatment (Summary)
Multimodality therapies are usual in IEM.
-
Residual disease manifestations will require management beyond the HSCT episode. This will include orthopedics, ENT, and speech therapies in lysosomal storage disorders (LSDs), as well as family and educational support in all.
-
Pharmacological enzyme replacement therapy (ERT) is used in MPSI but does not correct neurological disease as it does not cross the blood-brain barrier, and alloantibody formation might limit its utility in somatic disease. It is used to improve pre-HSCT performance, but it has not been shown to influence transplant outcomes.
1.7 Second-Line Treatment (Summary)
See Sect. 90.1.6., above.
1.8 Autologous HSCT
Gene-modified auto-HSCT approaches have been shown to improve outcomes in late infantile MLD as the graft delivers more enzyme than possible in a conventional HSCT. Similar approaches have been successful in X-ALD and are likely to be a significant part of the future of HSCT in IEM.
1.9 Allogeneic HSCT in MPSIH (Hurler), MLD, and X-ALD (See Table 90.2)
2 Osteopetrosis
2.1 Definition and Epidemiology
Osteopetrosis (OP) is a generic name of a number of rare single gene diseases characterized by sclerosis of the skeleton. At least nine forms are known with different modes of inheritance and severity, which cumulatively have an incidence ~1:100,000. The disease originates from reduced or complete lack of osteoclast function and, as a consequence, impairment of bone resorption
2.2 Diagnosis
In addition to the obligate increased bone density of all bones (X-ray), a combination of symptoms can be found in classical infantile osteopetrosis after birth. These symptoms include characteristic changes of the head (macrocephalus, frontal bossing, choanal stenosis), vision impairment (due to narrowed foramina), hematological insufficiency (thrombocytopenia, anemia, leukocytosis), hepatosplenomegaly (due to extramedullar hematopoiesis), and hypocalcemia (with secondary hyperparathyroidism). Cave: OP is a genetical and phenotypical heterogenous disease with atypical presentations (incomplete and/or delayed onset of symptoms). In these cases, an intensive work-up including spine biopsy and cranial MRI is recommended.
2.3 Classification
Osteopetrosis | |
---|---|
Infantile “malignant” autosomal recessive OP (ARO) | Clinical symptoms in infancy, death without HSCT usually in the first decade of life, biallelic mutations in TCIRG1, CLCN7, SNX10, TNFRSF11A/ RANK, and FERMT3/KINDLIN-3; HSCT indicated, if excluded: – “Neurodegenerative OP” (all OSTM1 and about half of CLCN7 cases) – “Extrinsic osteoclast defects” (TNFSF11/RANKL cases) |
Intermediate osteopetrosis | Clinical symptoms in the first decade, HSCT may be indicated in severe forms with hematological insufficiency and (imminent) visual impairment Specific from: CA2 deficiency (renal tubular acidosis with cerebral calcifications): HSCT is rarely indicated |
Benign osteopetrosis (ADO) | M. Albers Schoenberg (monoallelic CLCN7 mutations): HSCT not indicated |
2.4 Risk Factors
There is an increased risk of pulmonary hypertension (pre and post HSCT) and SOS/VOD (post BMT). The risk of non-engraftment and rejection increases with severity of disease and age.
2.5 Prognostic Index
Not available
2.6 First-Line Treatment (Summary)
Symptomatic, steroids may be beneficial to improve hematological symptoms
2.7 Second-Line Treatment (Summary)
Not available
2.8 Autologous HSCT
Preclinical trials for gene-modified auto-HSCT for TCIRG1 defects in preparation.
2.9 Allogeneic HSCT (See Table 90.3)
Recommended References
Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21:1106–9.
Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.
Boelens JJ, Wynn RF, O’Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–33.
Boelens JJ, Prasad VK, Tolar J, et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin N Am. 2010;57:123–45.
Chiesa R, Ruggeri A, Paviglianiti A, et al. Outcomes after unrelated umbilical cord blood transplantation for children with osteopetrosis. Biol Blood Marrow Transplant. 2016;22:1997–2002.
Consensus Guidelines of the EBMT and ESID at: https://esid.org/Working-Parties/Inborn-Errors-Working-Party-IEWP/Resources/UPDATED!-EBMT-ESID-GUIDELINES-FOR-HAEMATOPOIETICSTEM-CELL-TRANSPLANTATION-FOR-PI/Updated-Osteopetrosis-Consensus-Guidelines.
de Vernejoul MC, Schulz A, Kornak U. CLCN7-related osteopetrosis. 2007 Feb 12 [Updated 2013 Jun 20]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™. Seattle, WA: University of Washington; 2013. p. 1993–2013.
Driessen GJ, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant. 2003;32:657–63.
Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377:1630–8.
Prasad VK, Mendizabal A, Parikh SH, et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood. 2008;112:2979–89.
Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatr Blood Cancer. 2018;65:e27010.
Sobacchi C, Schulz A, Coxon FP, et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9:522–36.
Teti A, Schulz A. Haematopoietic stem cell transplantation in autosomal recessive osteopetrosis. In: Rajendram R, Preedy VR, editors. Stem cells and bone diseases. Vinood Patel Editors. Boca Raton, FL: CRC Press; 2013.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2019 EBMT and the Author(s)
About this chapter
Cite this chapter
Wynn, R., Schulz, A. (2019). Inborn Errors of Metabolism and Osteopetrosis. In: Carreras, E., Dufour, C., Mohty, M., Kröger, N. (eds) The EBMT Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-02278-5_90
Download citation
DOI: https://doi.org/10.1007/978-3-030-02278-5_90
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02277-8
Online ISBN: 978-3-030-02278-5
eBook Packages: MedicineMedicine (R0)